Delving into the Latest Updates on Aprogen, Inc. with Synapse

Overview

Basic Info

Introduction

Aprogen, Inc. engages in the manufacture, maintenance, and repair of heavy and chemical plant facilities. It operates through the following business divisions: Hardfacing, Metal, Nukon System, Manufactured Pharmaceuticals, Merchandised Pharmaceuticals, and Others. The company was founded on November 15, 1971 and is headquartered in Seongnam-si, South Korea.

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Bispecific antibody

Biosimilar

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Immune System Diseases	3
Hemic and Lymphatic Diseases	3

Top 5 Drug Type	Count

Bispecific antibody	2
Monoclonal antibody	2
Biosimilar	2
Antibody	1
Fc Fragment	1

Top 5 Target	Count

TAG-72(Tumor-associated glycoprotein 72)	1
CD20(B-lymphocyte antigen CD20)	1
CD43(JL1 antigen)	1
CA12(carbonic anhydrase 12)	1
TNF-α(Tumor necrosis factor α)	1

The aim of this study was to determine the potential for an additive effect from combining treatments with tolerogenic dendritic cells (tDCs) and etanercept (ETN) in a case of established type II collagen-induced arthritis (CIA).CIA mice were treated with type II collagen-pulsed tDCs either alone or in combination with ETN.We compared the effects of monotherapy with tDCs or ETN with the effect of combination treatment on the resultant rheumatoid arthritis using histopathol. analyzes and measurements of paw volumes, regulatory T cell populations, and cytokine levels.The clin. and histol. anal. revealed an additive effect from the combination therapy.Monotherapy with tDCs showed a tendency to ameliorate arthritis symptoms, while monotherapy with ETN reduced the paw swelling at 3 days after administration, but was not effective toward the end of the exptl. period.The combined treatment group also showed a marked inducement of the regulatory T cells and Th2 cytokines that are affected by tDCs compared with those of either untreated or ETN-treated CIA mice.ETN administered in combination with tDCs provided a substantially higher level of clin. benefit at the cellular level to CIA mice than the administration of either of these agents alone.

01 Apr 2006·Hybridoma

Monoclonal Anti-Thrombopoietin Antibodies Generated by Genetic Immunization

Article

Author: Kim, Keun-Soo ; Inn, Kyung-Soo ; Kang, Hyun-Jung ; Lee, Sangyoon ; Hong, Hyo Jeong ; Kim, Jung-Hwan ; Kim, Se-Yeon ; Lim, Nam-Kyu

Thrombopoietin (TPO) is a megakaryocyte growth and differentiation factor that is currently being investigated as a therapeutic for cancer patients undergoing myelosuppressive chemotherapy. We generated monoclonal antibodies (MAbs) specific for human thrombopoietin (hTPO) by genetic immunization using an hTPO expression plasmid and an adjuvant plasmid that encodes mouse granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). All genetically immunized mice exhibited a high humoral immune response. Splenocytes from these mice were used to generate hybridomas. Two MAbs, designated 2B9A10 and 4C16B15 (of IgG1 and IgG3 isotypes, respectively), were subsequently selected and produced. They specifically recognized and precipitated recombinant hTPO produced by mammalian cells and were effective in sandwich enzyme-linked immunosorbent assays (ELISAs) for hTPO quantitation. Our results demonstrate that these MAbs should be useful for purification and quantitation of hTPO in clinical and laboratory settings.

MoleculesQ3 · CHEMISTRY

Mealworm Oil (MWO) Enhances Wound Healing Potential through the Activation of Fibroblast and Endothelial Cells

Q3 · CHEMISTRY

ArticleOA

Author: Chung, Kyu Jin ; Lee, Jung-Hee ; Kim, Joung-Hee ; Chung, Tae-Wook ; Kim, Eun-Yeong ; Choi, Hee-Jung ; Kim, Keuk-Jun

Mealworm and mealworm oil (MWO) have been reported to affect antioxidant, anti-coagulation, anti-adipogenic and anti-inflammatory activities. However, the function of MWO in wound healing is still unclear. In this study, we found that MWO induced the migration of fibroblast cells and mRNA expressions of wound healing factors such as alpha-smooth muscle actin (α-SMA), collagen-1 (COL-1) and vascular endothelial growth factor (VEGF) in fibroblast cells. The tube formation and migration of endothelial cells were promoted through the activation of VEGF/VEGF receptor-2 (VEGFR-2)-mediated downstream signals including AKT, extracellular signal-regulated kinase (ERK) and p38 by MWO-stimulated fibroblasts for angiogenesis. Moreover, we confirmed that MWO promoted skin wound repair by collagen synthesis, re-epithelialization and angiogenesis in an in vivo excisional wound model. These results demonstrate that MWO might have potential as a therapeutic agent for the treatment of skin wounds.

100 Deals associated with Aprogen, Inc.

Login to view more data

100 Translational Medicine associated with Aprogen, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

Preclinical

Phase 1 Clinical

2

1

NDA/BLA

Approved

1

6

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Azelaic Acid	Acne Vulgaris More	Approved
Rituximab biosimilar(Aprogen, Inc.) ( CD20 )	Lymphoma More	NDA/BLA
AP20 (Aprogen)	Osteoarthritis More	Phase 1 Clinical
Adalimumab biosimilar(Aprogen) ( TNF-α )	Autoimmune Diseases More	Phase 1
AP-40 (Aprogen) ( CA12 )	Triple Negative Breast Cancer More	Preclinical